Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2943 Risk Stratification of Well-Differentiated Rectal Neuroendocrine Tumors

Introduction: How to screen patients with well-differentiated rectal neuroendocrine tumors (NETs) who had high risk to develop metastatic disease and poor survival was still less cleared.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Zhang Y, Guan X, Pan Y,

Keywords: rectal neuroendocrine tumors, metastasis, survival,

#2844 Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis

Introduction: Although rectal neuroendocrine tumors (NETs) with L-cell phenotype and small tumor size generally had better clinical behavior, the new 2019 WHO classification classified all rectal NETs are malignant without considering L-cell phenotype and small tumor size. Therefore, identifying biomarkers of rectal NETs is important to stratify the clinical behavior of rectal NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kim J

Authors: Kim J, Kim J, Oh E, Yang D, Hong S,

Keywords: Rectal neuroendocrine tumor, Chromogranin, Immunohistochemistry, Prognosis,

#2823 Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours

Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Tham W, Huang H, Tai W, Yan X, Ng C,

Keywords: Neuroendocrine tumours, PRRT,

#2767 Rectal NETs and Rectosigmoid Junction NETs May Need to Be Treated Differently

Introduction: Neuroendocrine tumours (NETs) are heterogeneous, and the incidence of colorectal NETs is rapidly increasing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cai W

Authors: Cai W, Ge W, Mao J, Hu h,

Keywords: Rectal neuroendocrine tumor, rectosigmoid junction, SEER database, Survival,

#2762 Finding the Risk Factors Associated with Neuroendocrine Tumors of Rectum

Introduction: Neuroendocrine tumors usually exhibits aggressive clinical behaviour and exclusive histopathological features. 60 to 70% of rectal NETs are asymptomatic.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fatima A

Authors: Fatima A, Zai S,

Keywords: colonoscopy, rectal NETs, low HDL-C level,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.